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MicroRNA (miRNAs) are negative regulators of gene expression and
can function as tumor suppressors or oncogenes. Expression
patterns of miRNAs and their role in the pathogenesis of hepato-
cellular carcinoma (HCC) are still poorly understood. We proﬁled
miRNA expression in tissue samples (104 HCC, 90 adjacent cirrhotic
livers, 21 normal livers) as well as in 35 HCC cell lines. A set of 12
miRNAs (includingmiR-21,miR-221/222,miR-34a,miR-519a,miR-93,
miR-96, and let-7c) was linked to disease progression from normal
liver through cirrhosis to full-blownHCC.miR-221/222, themost up-
regulated miRNAs in tumor samples, are shown to target the CDK
inhibitor p27 and to enhance cell growth in vitro. Conversely, these
activities can be efﬁciently inhibited by an antagomiR speciﬁc for
miR-221. In addition,we show, using amousemodel of liver cancer,
that miR-221 overexpression stimulates growth of tumorigenic
murine hepatic progenitor cells. Finally, we identiﬁed DNA dam-
age-inducible transcript 4 (DDIT4), a modulator of mTOR pathway,
as a bona ﬁde target of miR-221. Taken together, these data reveal
an important contribution formiR-221 in hepatocarcinogenesis and
suggest a role for DDIT4 dysregulation in this process. Thus, the use
of synthetic inhibitors of miR-221 may prove to be a promising
approach to liver cancer treatment.
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Hepatocellular carcinoma (HCC) is one of the most commonmalignant tumors in the world (1). Among the well estab-
lished risk factors for HCC, chronic infection with hepatitis B
(HBV) or C (HCV) virus is present in >85% of primary liver
cancers (2). Early studies indicated that only a few of the protein
changes detected so far can be validated at the RNA level (3).
miRNAs are thought to control gene expression at the post-
transcriptional level by causing mRNA degradation and/or re-
pressingmRNA translation (4). Evidence indicating thatmiRNAs
play an important role in various human cancers is now accumu-
lating (5), but only a few microtranscriptome HCC proﬁles, in-
volving limited numbers of samples, have been performed.
We present the miRNA expression proﬁle of a large number
of paired HCC-nontumor samples as well as liver cancer cell
lines. We observed unique miRNA expression signatures that
could distinguish malignant from adjacent cirrhotic tissues. We
provide evidence for a major contribution of miR-221 in liver
cancer cell proliferation and HCC development in vivo and
identify DNA damage-inducible transcript 4 (DDIT4) as a direct
target of miR-221.
Results
Twelve miRNAs Deﬁne a Signature for Liver Cancer. Our aim was
to identify miRNAs that are signiﬁcantly dysregulated during
cancer progression from normal liver to full blown HCC, through
the precancerous stage of cirrhosis. Thus, we proﬁled 21 normal
livers, 104 HCC, 90 paired cirrhotic tissues (Table S1), and 35
HCC-derived cell lines. According to our strategy, we made three
pairwise comparisons: (i) cirrhosis vs. normal liver, (ii) HCC vs.
normal liver, and (iii) HCC tissues compared to their respective
cirrhosis tissues. We hypothesized that a miRNA must be in-
volved in liver tumorigenesis if it is consistently dysregulated
through each step going from normal liver to cirrhosis and cir-
rhosis to HCC. miRNAs satisfying these requirements were then
examined in HCC cell lines to ensure that the miRNA signature
was truly a characteristic of expression in transformed liver cells
per se. The heat map of the miRNAs dysregulated in the last step
of progression (cirrhosis to HCC) is shown in Fig. 1. This com-
binatorial strategy identiﬁed the miRNAs signiﬁcantly dysregu-
lated in liver tumorigenesis: miR-106b, miR-21, miR-210, miR-
221, miR-222, miR-224, miR-34a, miR-425, miR-519a, miR-93,
and miR-96 were increased, and let-7c was lost during liver tumor
progression (Fig. 2A and Table S2).
We then determined which of the 12 microRNAs (miRNAs)
had the highest diagnostic value. Our purpose was to distinguish
between the tumors (139 tumors and cell lines) and the non-
tumor tissues (111 cirrhotic and normal livers). We used the
prediction test in BRB-ArrayTools to identify the classiﬁer sig-
nature with the lowest misclassiﬁcation error. As few as seven
miRNAs could classify (15% misclassiﬁcation error). The cross-
validation ROC curve for the seven miRNA classiﬁer is shown in
Fig. S1A. The miRNAs used in the ROC classiﬁer are under-
lined in Fig. 2A.
There were no signiﬁcant differences in miRNA expression
associated with p53 mutations, but we detected a signature asso-
ciated with β-catenin mutation (Table S2). Among the ﬁve miR-
NAs up-regulated 2- to 3-fold in cases of β-catenin gene mutation
was miR-34a, known previously as a p53 target, and miR-122, the
miRNA most highly expressed in hepatocytes (6, 7).
miR-221/222 Target p27. To validate the miRNA microarray data,
we carried out qPCR on RNA from 12 pairs of HCC and corre-
sponding nontumorous livers and tested four different members
of the progression signature (Fig. 2B and Fig. S1B). Statistically
signiﬁcant differences of expression levels were observed for all
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miRNAs investigated. In addition, we conﬁrmed trends observed
on microarray by qPCR for four different putative β-catenin
targets (Fig. 2B and Fig. S1C) (8).
We thendecided to investigate the rolesofmiR-221 andmiR-222
in detail. These miRNAs were chosen because of their consistently
high levels of expression in tumors, suggesting that they act as
Fig. 1. Heat map of miRNA expression in HCC: Tree showing the miRNAs deregulated in HCC vs. cirrhotic tissues (paired t test, P < 0.01). Each column in-
dicates the normalized log 2 ratio of the HCC/cirrhosis pairs. Clustering was performed with average linkage and uncentered correlation.
Fig. 2. miRNA signatures inHCC. (A) Intersection of SAManalysis for threeproﬁles. The intersection is shownamong thederegulatedmiRNAs in the three classes of
tissues: HCC, cirrhosis, and normal liver. Only the miRNA deregulated also in the HCC cell lines were considered. Red, up-regulated miRNAs; green, down-regulated
miRNAs. (B) ValidationofmicroarraybyqPCRofdifferentially expressedmiRNAs innontumoral (NT) vs. tumoral (T) liver tissuesand β-cateninmutated (β-catm) vs.wild-
type (β-catwt) specimens. The relative expression fold of eachmiRNA is normalized to RNU6B andmiR-140. P valueswere obtained by using a two-sided Student t test.
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oncomiRs in liver cancer. miR-221 and miR-222 share a high
degree of homology, are neighbors in human and mouse genomes,
and share common predicted targets (same seed sequence). On
Northern blot analysis, eachwas signiﬁcantly up-regulated in cancer
samples and cell lines when compared to NT or normal livers (P ≤
0.02), thus conﬁrming qPCR data (Fig. S2 A and B). We next ex-
amined someof their putative targets for repression in humanHCC
vs. nontumorous livers. The cyclin-dependent kinase inhibitor p27
(Kip1-CDKN1B) and the tyrosine-kinase receptor c-kit have been
identiﬁed as targets of miR-221 and miR-222 (9, 10). Because c-kit
is inconsistently expressed in liver, we focused on p27. Expression
levels of p27 in matched HCC-nontumor samples and liver cancer
cell lines were assessed by Western blot analysis and by qPCR. We
found a consistent decrease of p27 protein in samples over-
expressing miR-221/222 (Fig. S2C). However, there was no differ-
ence in the mRNA expression levels of p27 by qPCR, suggesting a
translational inhibition of p27 and not mRNA degradation (Fig.
S3A). Finally, in transfected HeLa and 293T cells, overexpression
with vectors expressingmiR-221andmiR-222was found to inducea
reduction of p27 protein levels (Fig. S3B).
miR-221/222 antagomiR Inhibits Cell Growth. To examine the role of
miR-221/222 on cell growth, we tested their effect on the
transformation properties of liver cancer and other tumor-
derived cell lines. After transfection of miR-221 precursor, we
observed that most cell lines formed larger colonies than controls
when plated at low density (Fig. 3A and Fig. S4A) (11). A few cell
lines (e.g., HeLa and PLC/PRF5), however, did not display any
changes, suggesting that in some contexts, an increased miR-221
level does not stimulate growth. Previous reports have indicated
that miR-221 and miR-222 overexpression may cause “oncogenic
addiction” (12). To address this point, LNA-modiﬁed oligonu-
cleotides speciﬁcally designed for miR-221 (antimiR-221) and
miR-222 (antimiR-222) knockdown were introduced by lip-
ofection into liver cancer cells. Malhavu, FOCUS, and HLE cells
were chosen for their high endogenous level of the miRNAs,
whereas PLC/PRF5 and Huh6 were used for their reduced ex-
pression (Fig. S2B). When plated at low density, the growth of
HLE was drastically inhibited (Fig. 3A), whereas the effect on
other cells was more subtle. Thus, to measure the impact of
synthetic inhibitors on liver cancer cell proliferation, a cell via-
bility assay was used (Fig. S4B). As shown in Fig. 3B and Fig.
S4C, treatment by antagomiRs, but not scrambled oligonucleo-
tide, reduced cell growth in liver cancer cell lines overexpressing
miR-221 and miR-222 by 35% (Malhavu) and 22% (FOCUS).
By contrast, no change in proliferation was observed in treated
PLC/PRF5 and Huh6 cells (Fig. 3B and Fig. S4C). Although, we
cannot exclude that transfection efﬁciencies are different between
high and low expressors, these data strongly suggest that over-
expressing cells became dependent on miRNA activity. When
introduced in combination, antagomiRs do not increase growth
inhibition suggesting that a saturation threshold is reached in the
four cell lines by a single antagomiR. A drastic reduction of miR-
221 and miR-222 levels (5- to 50-fold) was observed by qPCR in
high expressors, whereas a mild decrease (1.5- to 2-fold) was de-
tected in cell lines with low expression (Fig. 3B and Fig. S4C).
miR-221 Enhances Tumorigenesis in Vivo. These data prompted us
to investigate the role of both miRNAs in tumor development.
To this aim, we used a mouse model of liver cancer (13). P53−/−;
myc liver progenitors were infected with a retrovirus that over-
expresses miR-221, miR-222, and sh-APC (positive control), or
with an empty vector (Fig. 4A), and assayed for their ability to
form tumors in vivo. Expression levels of miR-221 and miR-222
constructs were monitored and found to be >50- and 10-fold
above the endogenous levels in transduced cells, respectively
(Fig. 4B and Fig. S4D). Subsequently, all constructs were in-
jected s.c. in a limited number of animals (n = 4 ﬂanks). In this
preliminary experiment, miR-222 did not accelerate tumori-
genesis when compared to empty vector or even uninfected cells.
We thus decided to focus on miR-221 and extended the series to
a total of 24 injected ﬂanks.
In mice injected with liver progenitors carrying miR-221, the
average latency for tumor apparition was decreased when com-
pared with empty vector. This difference was statistically sig-
niﬁcant (56 ± 5 versus 73.4 ± 5 days, P = 0.0142, Student’s t test;
Fig. 4 B andC). At 6 months follow-up, tumor penetrance was still
incomplete although similar for all retroviral constructs (80–90%
of injectedﬂanks).Weobserved a trend (P=0.0904) toward lower
rates of tumor-free survival for the miR-221-injected mice when
compared with empty vector-transduced hepatic progenitors (Fig.
4B). In addition, tumor progression, as measured by the time re-
quired to reach a volume of 1,000 mm3, was similar in miR-221-
and sh-APC-expressing cells and signiﬁcantly faster than in empty
vector-transduced cells (Fig. 4D).
DDIT4 Is a Target for miR-221. Individual miRNAs are believed to
target multiple mRNAs (12). Several miR-221 targets, all of them
being translationally inhibited, have been characterized in various
tumor types (see above) including p27-CDKN1B, p57-CDKN1C,
CKIT, and ESR1 (9, 14–16). To determine whether genes may be
suppressedbymiR-221 at theRNA level inHCC,we carried out an
Fig. 3. miR-221 inhibition impairs tumor cell growth. (A) HepG2 and HLE
cells were plated at low density after transfection by premiR negative con-
trol (NC), premiR-221 or LNA scrambled antagomiR (Scr antimiR), or LNA
antimiR-221. Cells were grown for 10 days, ﬁxed, and stained by crystal
violet. (B) Malhavu (miR-221 and miR-222 high expressor) and Huh6 (miR-221
and miR-222 low expressor) liver cancer cells were transfected with antimir-
221, antimiR-222, or a negative control and then plated out in 96-well plates.
Cell growth was measured by MTT assay at 72 h. Viability was identical for
cells treated with transfection reagent alone or scrambled antimiR. The
values are the means from three separate experiments done in triplicate. P
values were obtained by using a two-sided Student t test. miR-221 levels are
shown as measured by qPCR 24 h after transfection of LNA oligonucleotides.
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mRNA microarray analysis on 19 HCCs already screened for
miRNA expression. Fifteen inversely correlated transcripts (P <
0.05 for Pearson and/or Spearman coefﬁcients) contained putative
miR-221 target sites according to the prediction software (Tar-
getScan, PicTar-Vert, and MiRanda; Fig. S5 A and B).
To experimentally validate thatmiR-221 can target these genes,
3′UTRs of 11 different genes were subcloned downstream of a
Renilla reporter vector to analyze whether miR-221 can directly
targets these genes (Table S3). In 293T cells, premiR-221 but not
premiRnegative control, is able to reduceRenilla activity for six of
these constructs, indicating that this miRNA may directly target
these 3′UTRs. Conversely, reporter activity was stimulated in the
presence of the antimiR-221, indicating that endogenousmiR-221
can directly inﬂuence targeted protein levels (Fig. 5A). The ﬁve
other constructs failed to be negatively regulated by miR-221 (Fig.
S6A). Two highly conserved binding sites for miR-221, sub-
sequently named S1 and S2, are present in DDIT4 3′UTR (Fig.
S6B). To ascertain the direct effect of miR-221 onDDIT4,mutant
constructs targeting S1, S2, or S1+S2 were generated from human
and murine DDIT4 3′UTR. Mutations that disrupted the two
binding sites for miR-221 entirely restored luciferase activity (Fig.
5B and Fig. S6C), suggesting that miR-221, through binding to S1
and S2, directly regulates DDIT4 protein level. To address this
point, we transfected cells from different cell lines with precursor
miR-221. Western blot and qPCR experiments conﬁrmed that
miR-221 represses DDIT4 expression at both the protein and
RNA levels in the different cell types (Fig. 5C and Fig. S6D). A
similar decrease was observed for BNIP3L and TBK1 protein/
RNA levels, although the effect of miR-221 was weaker for these
two targets (Fig. 5C and Fig. S6D). Finally, we observed a sig-
niﬁcant inverse correlation between DDIT4 mRNA levels and
miR-221 expression in miR-221-transduced mouse tumors (Fig.
S6E), thus substantiating the relevance of this mouse model for
human HCC.
Discussion
The current knowledge about miRNA expression in HCC is still
rather preliminary (17–19). In this study, 104 HCC samples and
their corresponding nontumorous counterparts were analyzed by
using microarrays to determine miRNA expression proﬁles. The
results clearly distinguished the tumor proﬁle from the nonneo-
plastic tissue proﬁle. Overall, liver tumorigenesis is characterized
bymany up-regulated and repressedmiRNAs, potentially exerting
oncogenic and tumor-suppressive functions, respectively.
Our analysis identiﬁed a 12-miRNA signature that deﬁnes dis-
ease progression from normal liver to full-blown tumors through
liver cirrhosis. Four of them (miR-21, miR-221, miR-222, and
miR-224) are commonly found to be overexpressed across pre-
Fig. 4. miR-221 is protumorigenic in vivo. (A) Schematic representation of the transfer protocol using immortalized p53−/−;myc liver progenitors infected by
MSCV-derived retroviruses. (B) Kaplan–Meier curves showing the percentage of tumor-free injected mouse ﬂank. Mice were injected s.c. with p53−/−;myc
hepatoblasts previously infected by retroviruses expressing miR-221 or sh-APC in the PIG-MSCV vector. Each group corresponds to 24 ﬂanks/12 mice. Mice
were monitored starting at 3 weeks after injection. The histogram corresponds to miR-221 expression levels as measured by qPCR in the three types of
transduced liver progenitors. (C) Average latency for tumor appearance. Signiﬁcant differences of tumor onset was observed between miR-221 and empty
vector (*, P = 0.0142), sh-APC and empty vector (**, P < 1 10−4), and miR-221 and sh-APC (***, P = 0.0151). (D) Time required for tumor to reach 1,000 mm3.
Values are mean ± SD. Each mouse was killed when tumor reached 1,000 mm3. Signiﬁcant differences were observed between miR-221- and empty vector-
infected cells (*, P < 0.05) and between sh-APC and empty vector (**, P < 0.005).
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viously published proﬁles of the HCC microtranscriptome (8, 20–
22). Some belong to commonly up-regulated clusters, such asmiR-
106b andmiR-93 at 7q22 andmiR-221 andmiR-222 at Xp11 (23).
Interestingly, miR-34a, a target of p53, known to induce sen-
escence and/or apoptosis in vitro, was found to be overexpressed in
the progression signature, suggesting a potential versatility of
miRNA activity depending on the cell type investigated (24).
Dysregulation of miR-221 and miR-222 was found in the
miRNA progression signature involved in liver tumorigenesis.
They were previously shown to target the CDK inhibitors p27 and
p57 at the protein level. Despite the impact onmajor players in cell
cycle control, little is known about the role played in vivo by miR-
221 and miR-222. The mouse model of liver cancer indicates that
miR-221 stimulates the onset of tumors when compared with
vector-infected cells. miR-221 also promotes tumor progression,
signiﬁcantly shortening the mean time to death. Such pleiotropic
properties, however, appear milder when compared with the
outcomes observed in sh-APC-positive control in vivo. Given the
multiple potential targets of a single miRNA, such results are,
however, plausible and in line with the ﬁne-tuning effects usually
observed in miRNA experiments (25).
Despite sharing the same seed as miR-221, miR-222 did not
seem to accelerate tumors in preliminary experiments performed
on a restricted number of mice. miR-221 and miR-222 share only
three additional nucleotide identities 3′ to the seed. Previous
reports have shown that residues downstream of the seed—
particularly nucleotides 13–16, which all differ between miR-221
and miR-222—play a signiﬁcant role in miRNA activity (26). In
addition, expression levels of miR-222 in transduced hepato-
blasts were substantially lower than those observed for miR-221
(Fig. S4D). Whether the absence of accelerated tumorigenesis by
miR-222 is due to lower expression levels or to distinct functional
properties when compared to miR-221 remains to be clariﬁed.
For the most strongly repressed targets, mRNA destabilization
usually represents themajor component of repression (26).Although
published targetsofmiR-221belongexclusively to the translationally-
repressed category, we looked for miR-221-destabilized mRNAs in
HCC. According to prediction software, the expression of miR-221
was inversely correlated with a set of predicted targets in liver cancer.
Among them, DDIT4 was conﬁrmed in vitro both at the RNA and
protein levels. DDIT4 is an essential regulator of the mTOR kinase
through stimulation of the tuberous sclerosis tumor suppressor
TSC1/2 complex and as such is considered to be a putative tumor
suppressor (27). Thus, our data suggest the presence of another level
of disruption of the PTEN-PI3K-AKT-mTOR axis relevant to liver
tumorigenesis. Furthermore, another up-regulated member of the
progression signaturedeﬁned in thepresent report,miR-21, is known
to target the PTEN tumor suppressor (28). Remarkably, PTEN and
DDIT4 genes are only separated by 12 Mb on chromosome 10q,
implying that the heterozygous deletion of 10q and coup-regulation
of miR-21/miR-221 may act in concert in HCC. Thus, our data sug-
gest that in liver tumors where PI3K-PTEN-AKT-mTORmutations
remain conspicuously rare, the microtranscriptome may act as an
important regulator of this pathway, which is considered to be crucial
for hepatocarcinogenesis (29).
In conclusion, our ﬁndings suggest that the expression levels of
some miRNAs change gradually during the progression of liver
disease. A subset of these miRNAs are already considered as
bona ﬁde oncomiRs (miR-21, miR-221, miR-222, miR-93, miR-
96, and miR-106b), whereas some others (miR-210, miR-220,
miR-224, miR-425, and miR-519a) are apparently more HCC-
speciﬁc and merit further investigation. Among those miRNAs
present in the progression signature, miR-221 is capable of
stimulating tumor growth in vivo possibly through p27 and/or
DDIT4 down-regulation.
Materials and Methods
Patients and Cell Lines.A total of 104 patients (Table S1) and a collection of 35
hepatocellular carcinoma-derived cell lines were analyzed. The cell line col-
lection is described in ref. 30. This study was approved by an Institutional
Human Research review board (RBM 2005-019). Informed consent was ob-
tained for each patient. Total RNA was extracted with Tri-Reagent (Euro-
medex) according to the manufacturer’s speciﬁcations. HCV infection status
was determined by serology. p53 and β-catenin status were determined as
described in ref. 31.
Fig. 5. DDIT4 inhibition by miR-221. (A) Luciferase activity 72 h after co-
transfection of 293T cells with psiCHECK-2-UTRs vectors, premiR-221, premiR
negative control (NC), and LNA antimiR-221. Data are means ± SD of four in-
dependent experiments performed in triplicate. Renilla luciferase activity was
signiﬁcantly decreased for 3′ UTRs of positive controls (Kit, p27, CDKN1C) and
for DDIT4, CREBZF,MYBL1, TBK1, DKK2, and BNIP3L (P< 0.05, Student’s t test).
(B) Luciferase activity at 72 h in 293T cells cotransfected with premiR negative
control (NC,black) orpremiR-221 (gray) and luciferase reporters containing the
wild-type (WT) or mutated miR-221 binding sites (mS1 and mS2) of human
DDIT4 3′UTRor vector (V) (*, P< 0.01, Student’s t test). (C) 293T, Huh6, andNU.
K.-1 cells were transfected with vector expressing miR-221, miR-222, or empty
vector, andprotein levelswere checkedbyWesternblottingwith the indicated
antibodies. One representative of three independent experiments is shown.
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Microarray and Computational Analysis.Microarray analysis was performed as
described in ref. 32 and detailed in SI Materials and Methods. Two hundred
ﬁfteen mature miRNAs were studied in the expression table. Signatures
were detected by using SAM (q-value <0.05) in BRB-ArrayTools (33). The
microarray dataset was deposited in the ArrayExpress public database at the
European Bioinformatics Institute.
Quantitative PCR and Western Blot Analysis. Quantitative real-time PCR (qPCR)
was used to conﬁrm microarray data and measure miRNA impact on putative
targets. A TaqManassaywas used both formicRNAandmRNAanalysis (Applied
Biosystems) according to the manufacturer’s protocol (SI Materials and Meth-
ods). The TaqManMicroRNA assays for U6 RNA and miR-140 were used to nor-
malizethe relativeabundanceofmiRNA.Totalproteinextractswereprepared in
Laemmli buffer, loaded onto 10% Tris·HCl-ready gel (Bio-Rad), and transferred
to nitrocellulose membranes. Membranes were hybridized with antibodies
against p27 (610241; BD Biosciences), DDIT4 (0638-1-AP; Proteintech Group),
BNIP3L (ab8399; Abcam), TBK1 (ab40676; Abcam), tubulin (ab52866; Abcam),
and actin(C-2) (sc-8432; Santa Cruz Biotechnology). The secondary alkaline
phosphatase-conjugated antibody (T2191 or T2192; Applied Biosystems) was
detected by using CDP-Star Western blotting detection reagents (TROPIX).
Bands were quantiﬁed with ImageJ 1.38 Instrument software.
premiRs and antagomiRs Transfection. premiRs (Ambion, Applied Biosystems)
or antagomiR oligonucleotides (Eurogentec) were transfected (100 μM) using
siIMPORTER (Millipore) according to themanufacturer’s procedures. Negative
control premiR (Ambion) or scrambled antagomiR were transfected as con-
trols. Chemically modiﬁed antisense oligonucleotides (antagomiR) have been
used to inhibit miR expression in vitro. The sequences of antagomiR-221 and
antagomiR-222 used are as follows: 5′-GAAACCCAGCAGACAATGTAGCT-3′
and 5′-GAGACCCAGTAGCCAGATGTAGCT-3′, respectively. The scrambled an-
timiR sequence was 5′-CAGCTGAAGTAAATACCGACCAG-3′. Five 5′ and 3′
bases of each oligonucleotides were LNA (locked nucleic acid)-modiﬁed.
Transfected cells were plated at low density (2,500 cells per 10-cm plate),
grown for 7–10 days, ﬁxed, and stained by crystal violet as described in ref. 11.
To detect milder effects, cell growth was monitored 96 h after transfection by
the MTT [(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium] assay.
Mouse Model. E18 p53−/− liver progenitors were immortalized by Myc ex-
pression as described in ref. 34. Early passage immortalized progenitors were
transduced with a MSCV-based retroviral vector expressing miR-221, empty
vector, or an shRNA targeting APC (35). After puromycin selection, 3 million
cells per ﬂank were injected s.c. into irradiated NCR nu/nu mice (6-8 weeks of
age) 24 h after irradiation (400 rad). Injections were performed in the two
ﬂanks of each animal. Tumor volume was measured by caliper and calcu-
lated as length × width × depth × (pi/6).
Analysis of Putative miR-221 Targets. The different 3′UTRs were ampliﬁed
from human genomic DNA with the Advantage 2 PCR kit (Ozyme-Clontech).
Sequences of primers are available on request. PCR products were subcloned
to pGEM T-easy vector (Promega) and sequenced. 3′UTRs were then cloned
into psiCHECK-2 vector (Promega) and analyzed by using the Dual-luciferase
Reporter assay system (Promega). Mutant 3′UTRs were obtained by using
the QuikChange site-directed mutagenesis kit according to the manu-
facturer’s instructions (Stratagene). Details are provided in SI Materials
and Methods.
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